President Črtomir Fleisinger presents the vision and activities of the European Pharmaceutical Students’ Association (EPSA), representing 37 countries and 160.000 European pharmaceutical students. A strong collaboration is also established with EIPG in prefer to better inform its members about the possibilities offered to Pharmacy students within the industry
EFPIA and many other industrial and professional associations signed the "Joint Declaration for Pharmaceuticals in the Environment", asking the EU Commission a transparent and collaborative dialogue during the drafting of the new European strategy to prevent risk for the environment
The expertise of the different national competent authorities of the European network, the workload associated with each product and its legal basis are the main criteria established by EMA to redistribute the UK centrally authorised product portfolio as part of the preparation to the Brexit
Many themes have been discussed at the EIPG General Assembly 2018, that took place in Casablanca, Morocco, on 4-6 May. EIPG Executive Director Jane Nicholson reports on reached achievements and plans for the future
Access to medicines is at the center of the Bulgarian presidency of the European Council and related issues have been discussed during the Conference organised in Sofia on March 6th
The European Commission has published a report on the off-label use of pharmaceuticals, discussing the current framework and possible future options to better regulate the access to medicines for not approved indications
Morocco is an emerging player in the global pharmaceutical market, thanks to its stable political framework and central localisation in the Mediterranean area. Both domestic and multinational pharmaceutical companies are present in the country. The local government is also supporting an ambitious health insurance program.
In March EIPG submitted its comments to EMA with reference to the targeted stakeholder consultation on Annex 1, responded to the questionnaire of the GMP/GDP IWG and QWP on the auditing of active pharmaceutical ingredients manufactures and attended the Industry stakeholder meeting on Brexit organised by EMA.
Topics of the new IMI Call 14 include control of immune-mediated diseases, non-invasive imaging, machine learning for drug discovery and decentralised clinical trials. The deadline to present applications is 14 June 2018.
China FDA proposed a collaborative project on the harmonisation of the clinical evaluation of medical devices at the international level during the 13th IMDRF meeting, that has been unanimously accepted. The new effort will aim to develop uniform standards and might result into the future amendment of the relevant European legislation on medical devices.